AI-driven drug turnaround company Ignota Labs has closed a £5.5m seed funding round to expand its pipeline. The Cambridge-based BioTech plans to do this by acquiring additional distressed assets. Funding will also be used for advancement into early-stage clinical trials of their first asset – a PDE9A inhibitor. Ignota Labs is looking to address the … Continue reading Cambridge BioTech raises £5.5m to address $400bn annual issue